



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/14, 47/20, 47/26 A61K 47/32, 47/38, 47/18 A61K 47/14	A1	(11) International Publication Number: WO 92/01442 (43) International Publication Date: 6 February 1992 (06.02.92)
--	----	--

(21) International Application Number: PCT/EP91/01330

(22) International Filing Date: 16 July 1991 (16.07.91)

(30) Priority data:
9015824.7 18 July 1990 (18.07.90) GB(71) Applicant (for all designated States except US): FARMITAL-
IA CARLO ERBA S.R.L. [IT/IT]; Via Carlo Imbonati,
24, I-20159 Milan (IT).

(72) Inventors; and

(75) Inventors/Applicants (for US only) : ADAMI, Marco [IT/
IT]; Via Fiuggi, 56, I-20159 Milan (IT). DALLA CASA,
Rosanna [IT/IT]; Via Guido De Ruggiero, 69, I-20142
Milan (IT). GAMBINI, Luciano [IT/IT]; Via Piave, 16,
I-20010 Cornaredo (IT). MAGRINI, Roberto [IT/IT];
Via Don Minzoni, 45, I-20091 Bresso (IT). MARIANI,
Rosaria [IT/IT]; Via Carlo Marx, 12, I-20033 Desio (IT).
PERRONE, Giovanni [IT/IT]; Via Melchiorre Gioia,
131, I-20125 Milan (IT).(74) Agents: WOODS, Geoffrey, Corlett et al.; J.A. Kemp &
Co., 14 South Square, Gray's Inn, London WC1R 5LX
(GB).(81) Designated States: AT (European patent), AU, BE (Euro-
pean patent), CA, CH (European patent), DE (Euro-
pean patent), DK (European patent), ES (European pa-
tent), FR (European patent), GB (European patent), GR
(European patent), IT (European patent), JP, LU (Euro-
pean patent), NL (European patent), SE (European pa-
tent), US.

Published

With international search report.

(54) Title: STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A FIBROBLAST GROWTH FACTOR

(57) Abstract

A stable lyophilised formulation of a fibroblast growth factor (FGF) comprises the FGF, a pharmaceutically acceptable bulking agent and either (a) an alkali metal salt of a carboxyalkyl cellulose, or (b) a polyoxyethylene sorbitan fatty acid ester and cysteine.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU ⁺	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

⁺ It is not yet known for which States of the former Soviet Union any designation of the Soviet Union has effect.

- 1 -

STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING A
FIBROBLAST GROWTH FACTOR

The present invention relates to freeze dried (lyophilized) compositions containing fibroblast growth factor (FGF) having human mitogenic activity, in particular, human basic fibroblast growth factor (bFGF).

- 5 The bFGF may be natural or produced by recombinant means.

Safe handling and administration of protein drugs represent significant challenges to pharmaceutical formulators as proteins possess unique chemical and physical properties which pose difficult stability
10 problems: a variety of degradation pathways exist of proteins, involving both chemical and physical instability. These macromolecules are also at risk from microbial degradation due to adventitious contamination of the solutions during purification or storage. All these
15 considerations are especially critical for the pharmaceutical manufacturer who is formulating and packaging these agents with the expectation of an economically favorable shelf-life. Thus, a thorough preformulation programme is an essential step for protein
20 drugs, to solve their possible formulation problems. In addition, a range of stability-indicating test methods is necessary, in order to ensure shelf-life is maintained.

Many biological materials, including proteins which will rapidly deteriorate even in frozen solutions, can be
25 kept in a viable state for long periods of time by lyophilization of the material. Lyophilization (also known as freeze drying) is a process of drying a composition in which water is sublimed from the composition after it is frozen. The particular advantages of this process are that
30 materials which are relatively unstable in an aqueous solution can be processed and filled into dosage containers in the liquid state, taking advantage of the relative ease of processing of a liquid; dried without elevated

- 2 -

temperatures, thereby eliminating adverse thermal effects; and then stored in the dry state in which there are relatively few stability problems. Thus, the product can be stabilized against loss of biological activity to
5 provide a long shelf life.

It is often impractical to design formulations based merely on the lyophilization of the bulk drug. This is so because usually the amounts of the drug used in the formulation will be very small. This is a problem because
10 during the lyophilization process the drug can be pulled from the lyophilization container by the vacuum employed in the process. Furthermore, many polypeptides are relatively unstable when lyophilized in small concentrations. They can absorb to product packaging and lose activity. Many
15 lyophilized pharmaceutical compositions rely on the use of diluent or extender to increase the amount of solid present during the lyophilization process and thereby eliminate the problems associated with lyophilization of small amounts of bulk drug.

20 EP-A-0 308 238 describes stable lyophilized compositions comprising a polypeptide growth factor having human mitogenic activity and a water soluble or water swellable, pharmaceutically acceptable polymer capable of imparting viscosity to a reconstituted solution of the
25 composition. As a growth factor, epidermal growth factor (EGF) is particularly mentioned.

The present invention provides a lyophilized composition which comprises a fibroblast growth factor (FGF), a pharmaceutically acceptable bulking agent and
30 either:

(a) an alkali metal salt of a carboxyalkyl cellulose, or

(b) a polyoxyethylene sorbitan fatty acid ester and cysteine.

35 In this application, FGF includes the class of polypeptides that have biological activity similar to that

- 3 -

exhibited by the natural human FGF polypeptide. Thus, FGF includes acidic and basic FGF, such as human FGF produced by recombinant DNA techniques or derived from natural sources, as well as closely related mammalian FGF, eg.

5 bovine, murine or rodent. FGF also includes chemically modified FGF such as a FGF in which at least one of the four cysteine aminoacid residues are derivatized. A FGF for use in the invention may therefore be a carboxymethylated FGF wherein the -SH group of one or more
10 of cysteine residues has been converted into a -S-CH₂-COOH group. Any bFGF molecule as described in, for instance, WO 86/07595; WO 87/01728; EP-A-0226181; Abraham et al, EMBO J. 5, 2523-2528, 1986; or Lobb, Eur. J. Clin. Invest. 18, 321-336, 1988; may be usefully employed in the invention.

15 A mixture of bFGFs may be employed. This may be an approximately 50:50 mixture of:

- a 154 amino acid human bFGF having the amino acid sequence of the 155 amino acid form which is reported by Abraham et al and shown in SEQ ID NO:1 but without the
20 N-terminal Met residue; and
- a 153 amino acid human bFGF having the amino acid sequence shown in SEQ ID NO:1 but without the N-terminal Met and Ala residues.

Human basic FGF, for example produced by
25 recombinant DNA techniques, is preferred for use in the present invention. A specific carboxymethylated FGF for use in the invention is the 146 amino acid form of bFGF, as described in WO 87/01728, wherein the two cysteine residues at positions 69 and 87 are irreversibly blocked by
30 carboxymethyl groups, i.e. as -S-CH₂-COOH groups. This specific carboxymethylated FGF will be referred to as CM-FGF. It is therefore a bFGF having the amino acid sequence from position 10 to position 155 shown in SEQ ID NO:1 in which the Cys residues at positions 78 and 96 in SEQ ID
35 NO:1 are carboxymethylated.

In one embodiment of the present invention the

- 4 -

composition further includes an antioxidant, selected to prevent substantially oxidation of the FGF when the composition of the invention is stored over an extended period of time. eg. 1-3 months. Preferably the anti-
5 oxidant is dithiothreitol (DTT). When present, the antioxidant will typically be present in an amount of from 0.01% to 100%, preferably from 0.1% to 25% by weight of the bulking agent.

The bulking agent is any bulking agent suitable for
10 use in freeze-drying. The bulking agent generally has good properties as a rigidizer, in order to avoid melt-back or collapse of the product during lyophilization. Suitable pharmaceutically acceptable bulking agents include
15 mannitol, lactose, polyvinylpyrrolidone, galactitol and trehalose. Of these, mannitol is preferred. The amount of FGF in the composition of the present invention is typically from 0.01% to 5%, preferably 0.1 to 1%, of the weight of the bulking agent.

It has surprisingly been found that the FGF in
20 admixture with a pharmaceutically acceptable bulking agent may be stabilized by the presence of an alkali metal salt of a carboxyalkyl cellulose, for example a carboxy C₁₋₄ alkyl cellulose. The alkali metal salt may be for example the sodium salt or potassium salt. This component will
25 usually be present in an amount from 0.1% to 50%, preferably from 2.5% to 10%, by weight of the bulking agent. Sodium carboxymethyl cellulose is preferred. The use of a cellulose salt surprisingly provides stability to compositions of the present invention which is not
30 obtainable from neutral alkyl cellulose, eg. methyl cellulose.

Compositions of the present invention may also be stabilized by the use of a polyoxyethylene sorbitan fatty acid ester and cysteine. It has surprisingly been found
35 that these two components act synergistically to provide increased stability. Examples of polyoxyethylene sorbitan

- 5 -

fatty acid esters include partial C₁₂₋₂₀ saturated or unsaturated fatty acid esters of sorbitol and its mono- and di-anhydrides copolymerised with ethylene oxide. Typically, from 10 to 40, for example about 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides will be present. Polyoxyethyle sorbitan fatty acid esters are known generally as polysorbates. Examples of polysorbates include polysorbate 20 (polyoxyethylene 20 Sorbitan Monolaurate, Chemical Abstracts reference No 9005-64-5), which is a mixture of partial lauric esters of sorbitol and its mono- and di-anhydrides copolymerised with approximately 20 moles of ethylene oxide for each mole of sorbitol and its anhydrides, polysorbate 40 (polyoxyethylene 20 sorbitan monopalmitate, CAS No 9005-66-7), polysorbate 60 (polyoxyethylene 20 sorbitan monostearate CAS No 9005-67-8), polysorbate 65 (polyoxyethylene 20 sorbitan tristearate, CAS No. 9005-71-4, polysorbate 80 (polyoxyethylene 20 sorbitan mono-oleate, CAS No 9005-65-6) and polysorbate 85 (polyoxyethylene 20 sorbitan trioleate CAS No 9005-70-3). The amount of the polyoxyethylene sorbitan fatty acid ester is preferably from 0.01% to 25%, most preferably from 0.1% to 1% by weight of the bulking agent. The amount of cysteine in compositions of the invention is preferably from 0.001% to 1%, most preferably 0.01% to 0.1% by weight of the bulking agent.

Compositions of the present invention will normally be formulated in bulk solution prior to freeze drying. The bulk solution may be freeze-dried in any quantity, although preferably the bulk solution will be divided into aliquots containing from 5 to 500, for example from 10 to 100 and preferably 50 micrograms of FGF. These aliquots will be freeze-dried separately, eg. in individual glass vials. Before the solution is freeze-dried, it may be sterilized for example by filtration. A 0.2 μ m nylon membrane filter may be used for this purpose. Using HPLC analysis carried out after such filtration, we have found that FGF is

- 6 -

consistently recovered on a quantitative basis.

Lyophilization essentially consists of the following steps. First, the solution to be freeze-dried is frozen at a temperature below its eutectic temperature in an evacuation chamber. The chamber is then evacuated, usually below 13.3 Pa (0.1 Torr). Ice is sublimed on a cold condensing surface at a temperature below that of the product, the condensing surface being within the chamber or in a connecting chamber. Then, heat is introduced to the product under controlled conditions, thereby providing energy for sublimation at a rate designed to keep the product below its eutectic temperature. A typical freeze-drying cycle is as follows:

(a) Freeze at -45°C , and maintain this temperature for four hours.

(b) Primary drying at -45°C to $+25^{\circ}\text{C}$ for approximately twelve hours, with vacuum level less than 13.3 Pa (0.1 Torr) and a condenser temperature of -60°C .

(c) Secondary drying at $+25^{\circ}\text{C}$ for approximately eleven hours, with the same vacuum and condenser temperature as described in (b) above. We have found this freeze-drying cycle to be suited to preparation of batches of FGF produced in accordance with the present invention. However, it will be apparent to those of ordinary skill in the art that variations of this protocol which do not substantially alter the stability of the FGF may be made.

Aliquots of the composition of the present invention may be dispensed into sterile vials. Sterile glass vials can be suitable. It is known that proteins adhere to glass surfaces, and we have found that when the lyophilized compositions of the present inventions is reconstituted in a glass vial, some loss of protein due to adhesion occurs. However, we have found that coating the glass vials with silicone emulsion (Pharmaceutical grade) in order to minimise sticking successfully overcomes this problem.

- 7 -

We have also observed that when the glass vials are sealed with conventional rubber stoppers, losses of protein may occur due to absorption of the FGF to the rubber surfaces. The use of fluororesin laminated butyl rubber stoppers prevents this absorption process.

The lyophilized compositions of the present invention may be stored under air or vacuum. Preferably however, they will be stored under an inert gas, eg. nitrogen.

The lyophilised composition of the invention therefore consists essentially of a FGF, a pharmaceutically acceptable bulking agent and either (a) an alkali metal salt of a carboxyalkyl cellulose or (b) a polyoxyethylene sorbitan fatty acid ester and cysteine.

The freeze-dried composition of the invention may be reconstituted using any pharmaceutically acceptable solvent. Preferably, the solvent used will provide a reconstituted solution with a pH of between 5.0 and 7.0. Preferably, a 0.9% solution of sodium chloride (i.e. physiological saline) is the reconstitution solvent. Optionally, the solution contains an effective amount of an anti-microbial preservative agent. Benzalkonium chloride at a concentration of about 0.005% by weight is particularly suitable, since its efficacy is well documented and because it is commonly used in pharmaceutical formulations, for example as an ophthalmic preservative. We have found that 0.005% by weight benzalkonium chloride effectively inhibits microbial activity in reconstituted solutions of the present invention.

FGF is a growth factor that plays a role in the regulation of growth of normal human cells. FGF has utility in stimulating wound healing and the growth of fibroblast cells. The present invention thus also provides a kit containing the lyophilized composition described

- 8 -

above in a sterile vial and a sterile diluent for reconstitution of the lyophilized composition. The invention further includes a method of preparing an aqueous FGF solution which comprises reconstituting the freeze dried composition of the present invention with an aqueous diluent, eg. the pharmaceutically acceptable solvent described above. The compositions or kits according to the present invention are useful in a method of treatment of the human or animal body, eg. in the treatment of wound healing.

The Examples which follow illustrate aspects of the present invention.

In the following Examples, the FGFs used are the basic FGF FCE 26184 which is a recombinant protein drug available from Farmitalia Carlo Erba Biotechnology Development Department and CM-FGF which is a chemically modified protein obtained from bFGF (146 amino acid form). Their preparation is described below in the Preparation Examples. bFGF and CM-FGF are obtainable as a frozen bulk solution at a concentration of active substance of approximately 2.0 mg/ml for bFGF and 1.1 mg/ml for CM-FGF (this concentration is expressed as protein content measured by the biruet reaction, the solvent is at pH 6.0 obtained with a 10 μ M phosphate buffer).

We have observed that thawing these bulk solutions and diluting them to a concentration of about 50 μ g/ml using a 2% mannitol solution does not affect protein stability. HPLC analyses of diluted solutions show active drug substance (bFGF or CM-FGF) is quantitatively recovered.

Preparation Example 1: Preparation of bFGF (FCE 26184)

The construction of the synthetic DNA sequence for bFGF and of the expression plasmid carrying such sequence was performed according to the procedure described in

- 9 -

EP-A-363675. The fermentation and purification process was carried out as follows:

(a) Fermentation process

A bacterial strain, E. coli type B, from the Institute
5 Pasteur collection, was transformed with a plasmid carrying both the human gene coding for bFGF and the gene for tetracycline resistance. This transformed strain was used for the production of recombinant non-glycosylated h-bFGF (human bFGF). A Master Cell Bank (15 freeze-dried vials)
10 and a Working Cell Bank (W.C.B.) (70 vials stored in liquid nitrogen at -190°C) of this strain were prepared. The content of one vial of W.C.B. was used as the inoculum for the fermentation phase.

The fermentation process was carried out in 10 l
15 fermentors filled with 4 l of culture medium. Tetracycline hydrochloride was added to the medium in order to maintain the conditions of strain selection. After 20 hours of growth at 37°C the final biomass was 42 ± 2 g/l dry weight, and the production of bFGF was 2500 ± 500 mg/l as measured
20 by comparative gel electrophoresis.

Enrichment in pure oxygen was required during the fermentation phase in order to allow a large bacterial growth.

(b) Initial purification

25 The cells (microorganisms) were separated from the total fermentation broth by centrifugation. The resulting pellet was resuspended in a sodium phosphate buffer containing sodium chloride. A minimum of 3 passages through a high pressure homogenizer were necessary for efficient cell
30 breakage. The resulting cell lysate was clarified by centrifugation and the supernatant was collected for further processing.

(c) Purification

The clarified supernatant was loaded on a column of

- 10 -

Sepharose (Trade Mark) S Fast Flow (cation exchanger) and the product was eluted from this column using a gradient of increasing sodium chloride concentrations in a phosphate buffer. The product was further purified on a column of

- 5 Heparin Sepharose (Trade Mark) 6 B by eluting with a gradient of increasing sodium chloride concentration in a phosphate buffer. Finally a buffer exchange was made on a Sephadex (Trade Mark) G25 resin to obtain the product in the bulk product buffer (Sodium phosphate -EDTA).

10 (d) Column sanitization

Sepharose S Fast Flow and Sephadex G25 columns were sanitized by washing with sodium hydroxide solutions. Heparin Sepharose was washed alternatively with solutions at pH = 8.5 and pH =5.5 containing 3M sodium chloride.

- 15 In this way, there was obtained bFGF designated FCE 26184. This is an approximately 50:50 mixture of:
- a 154 amino acid human bFGF having the amino acid sequence of the 155 amino acid form which is reported by Abraham et al and shown in SEQ ID NO:1 but without the N-
 - 20 terminal Met residue; and
 - a 153 amino acid human bFGF having the amino acid sequence shown in SEQ ID NO:1 but without the N-terminal Met and Ala residues.

Preparation Example 2: Preparation of CM-FGF

- 25 To a solution of 100 mg of recombinant human bFGF (146 aminoacid form), obtained as described in WO 87/01728, in 110 ml of 25 mM phosphate buffer pH 8.0/5 mM EDTA, was added 400 mg of iodoacetic acid in 110 ml of the same buffer. The reaction mixture was allowed to stand at room
- 30 temperature for two hours in the dark. The reaction mixture was then directly loaded on a MonoS column (HR 10/10, Pharmacia) equilibrated in 25 mM phosphate buffer pH 7.5. In order to eliminate the reagent excess, the column was extensively washed with the equilibration buffer and

- 11 -

the carboxymethylated bFGF (CM-FGF) was eluted with a linear gradient from 0 to 1 M NaCl in 25 mM phosphate buffer pH 7.5. The CM-FGF containing fractions were desalted on a Sephadex G-25 column (Pharmacia) equilibrated
5 in 10 mM phosphate buffer pH 6.0/0.1 mM EDTA.

EXAMPLE 1

We have found that the presence of an antioxidant, eg. 1,4-dithiothreitol (DTT) is effective in protecting the protein in solution against oxidation.

10 However, in spite of its good protective effect in solution, DTT does not inhibit degradation of the protein in the freeze-dried state when it is stored over an extended period of time. In fact a 50 μ g freeze-dried formulation of bFGF containing mannitol as a bulking agent
15 and DTT as antioxidant did not yield an acceptable stability: a potency loss (HPLC method) of about 10% was detected after storage for one week at 35°C and 25°C. Thus the need existed to incorporate a protective agent into the formulation.

20 According to P. P. De Luca and M. W. Townsend (Journal of Parenteral Science and Technology. vol. 42, No. 6, Nov.-Dec. 1988, page 190) "prevention and reduction of conformational modifications in proteins due to freezing, drying, or extended storage may be attained through the use
25 of lyo- or cryo-protectants. A lyoprotectant is being defined as a compound that stabilizes and prevents the degradation of a protein both during freeze-drying and afterwards, during storage, whereas a cryoprotectant only infers protection from freezing damage".

30 Based on these theoretical considerations, experimental work was thus undertaken to determine the FCE 26184 and CM-FGF protective capacity of a number of compounds which might act as lyoprotectants.

Hydroxypropylmethylcellulose (HPMC), sodium

- 12 -

carboxymethyl cellulose (NaCMC), methylcellulose (MC), hydroxyethylcellulose (HEC), polyvinyl alcohol (PVA), sodium chloride, glycine, cysteine and albumin were selected as possible protective agents. Solutions
5 containing bFGF (50 µg/ml), mannitol (20 mg/ml as bulking agent, DTT (either 0.5 or 0.1 mg/ml) as antioxidant, and a suitable concentration of each potential stabilizer were prepared aseptically, filled into vials (nominal volume: 1.0 ml), and freeze-dried. The effect of storage on the
10 protein potency in the final freeze-dried formulation was checked through accelerated stability studies (35°C).

Basic experimental results are summarized in Table 1. As already mentioned, the freeze-dried formulation containing mannitol and DTT underwent 10% potency loss
15 after one week storage.

A loss of the same extent was observed when cysteine was added with the aim of exploiting its synergism with DTT.

The presences of a lyoprotectant, such as NaCMC
20 significantly improved protein stability. Other cellulose derivatives (HPMC, HEC, MC) proved to be ineffective as stabilizers (data are presented in Table 1 only for MC, but other derivatives behaved similarly).

PVA, sodium chloride, glycine and albumin proved to
25 be highly incompatible with bFGF. Polysorbate 80 or cysteine proved to be ineffective, if used alone. However the combination of polysorbate 80 and cysteine surprisingly worked well as a stabilizer. Furthermore, either polysorbate 80 or cysteine acted synergistically with
30 NaCMC.

Data presented in Table 1 put into evidence the key role played by the lyoprotectants as stabilizing agents for the protein in the freeze-dried state. Possible mechanism for the protective capacity of these compounds could reside
35 in their ability to prevent the segregation of water from the protein in the freeze-dried preparation. In each

- 13 -

freeze-dried formulation tested, water is present (as residual humidity) to an extent exceeding that of the drug and sufficient to maintain the protein in a hydrated conformation. Any challenge (temperature: low, or high; 5 solvents) which disrupts the shell of water loosely coordinated by the protein structure brings about a protein inactivation through denaturation or aggregation. Stabilizers such as NaCMC are able to tightly coordinate water molecules through either their hydrophilic structure 10 of their polar carboxylic group. As consequence, they maintain the protein microenvironment in a hydrated state.

Other cellulose derivatives, such as HPMC, MC, and HEC, tested as protecting agents, provided to be ineffective, most probably because they lack carboxylic 15 group.

The low stabilizing activity of polysorbate 80 might be expected, due to the low coordination power of this additive towards the water molecules. On the contrary, the synergistic effect of polysorbate 80 with 20 both cysteine and NaCMC was quite unexpected.

- 14 -

Table 1 - FCE 26184 preformulation studies
Accelerated stability results of different
freeze-dried formulations, containing bFGF (50
mcg), Mannitol (20 mg), and DTT (0.1 mg)

5

COMPOSITION				Residual FCE 26184 % (HPLC assay) after 1 week at		
MC	NaCMC	Cysteine	Polysorbate 80	4°C	25°C	35°C
-	-	-	-	91.0	88.0	89.0
1	-	-	-	59.3	-	32.0
-	-	0.02	-	93.0	83.0	70.0
-	1	-	-	99.0	102.0	102.0
-	-	-	0.1	92.0	88.0	88.0
-	-	0.01	0.01	106.0	105.0	112.0
-	0.01	-	0.05	96.0	100.0	97.0
-	0.01	0.01	-	108.0	114.0	113.0

Experimental results for CM-FGF are summarized in Table 2, in which n.d. means not determined. Solutions containing CM-FGF (50 µg/ml), mannitol (20 mg/ml) as bulking agent, DTT (0.1 mg), and a suitable concentration of each potential stabilizer were prepared aseptically, filled into vials (nominal volume 1.0 ml), and freeze dried. The effect of storage on the protein potency in the final freeze dried formulation was checked through accelerated stability studies (35° C/45° C). As already seen for bFGF, Na-CMC significantly improves CM-FGF stability.

TABLE 2 - CM-FGF preformulation studies. Accelerated stability results of different freeze dries formulations, containing CM-FGF (50 µg) and mannitol (20 mg)

COMPOSITION (mg/vial)		RESIDUAL CM-FGF (HPLC ASSAY)					
NaCMC	CYSTEINE	Polysorbate 80	DTT	T=0	15 DAYS 35°C	4°C	30 DAYS 25°C
---	---	---	---	(%) 100.00	n.d.	99.86	83.36
---	---	---	0.10	(%) 100.00	91.13	82.29	76.82
1.00	---	---	---	(%) 100.00	87.58	n.d.	96.58
1.00	---	---	0.10	(%) 100.00	n.d.	104.99	101.31
							105.79
							74.30
							72.77
							81.30

- 16 -

HPLC assay of the samples was performed using the following materials, equipment and solutions, under the conditions provided below.

Materials:

bFGF frozen bulk solution, working standard
CM-FGF frozen bulk solution, working standard
Acetonitrile, HPLC grade
Water, HPLC grade
Trifluoroacetic acid, analytical grade
1,4-dithiothreitol, analytical grade

Equipment:

- . Liquid chromatograph Milton Roy model CM 4000, or equivalent, equipped with:
- .. chromatographic column: (length 250 mm, internal diameter 4.6 mm) filled with Vydac 218TP54 300 Å (average particle size 5 mcm), or equivalent
- .. injection valve: Rheodyne model 7125, or equivalent, fitted with a 100 mcl sample loop
- .. detector Shimadzu model SFD 6A, or equivalent
- .. integrating recorder: SP 4270 (Spectra-Physics), or equivalent
- . Membrane filter, 0.22 µm porosity, Millipore Durapore GVWP, or equivalent
- . High precision laboratory glassware
- . Plastic pipet tips (Gilson)
- . Automatic pipets (Gilson)
- . Disposable plastic microtubes, capacity 2.5 ml (Eppendorf)

Solutions:

- . Mobile phase (A) consisting of water, containing 0.1% of trifluoroacetic acid (w/v), filtered through the membrane filter and deaerated.

- 17 -

- . Mobile phase (B) consisting of 95% acetonitrile-5% water containing 0.1% of trifluoroacetic acid (w/v), filtered through the membrane filter and deaerated.
- . 1.4-dithiothreitol solution
Prepare a solution containing about 1 mg/ml in HPLC grade water
- . Standard solution
Transfer a suitable volume of bulk solution of bFGF or CM-FGF working standard, accurately measured, into a disposable plastic microtube.
Dilute with a suitable volume of 1,4-dithiothreitol solution in order to obtain a final solution containing about 50 mcg/ml of bFGF or CM-FGF.
The standard solution must be freshly prepared and used within a working day.
- . Sample solution
Prepare the sample solution using at least five freeze-dried vials.
The content of each vial dosed at 50 mcg of bFGF or CM-FGF is dissolved in 1.0 ml of HPLC grade water, then a pool is made with all prepared solutions.

Chromatographic (HPLC) conditions:

The standard and sample solution are alternatively injected at least 3 times into the liquid chromatograph under the following experimental conditions:

Column temperature	:	room temperature ($22 \pm 2^\circ \text{C}$)
Mobile phase flow-rate	:	1 ml/min
Analytical wavelength	:	$210 \pm 1 \text{ nm}$

- 18 -

Gradient conditions

:	<u>time (min)</u>	<u>A%</u>	<u>B%</u>
	0	75	25
	20	60	40
	25	60	40
	30	75	25

Detector sensitivity

: the detector "computer"
output is connected to
integrator for maximum
sensitivity

Injection volume

: 100 mcl

Integrating recorder

attenuation

: 256

Chart speed

: 0.5 cm/min

- 19 -

EXAMPLE 2

a) Formulation of bFGF composition stabilised with sodium carboxymethylcellulose.

	<u>Per vial***</u>	<u>per 2,000 vials ***</u>
FCE 26184 *	0.0604 mg*	120.8 mg*
Sodium carboxymethyl-cellulose	1.0500 mg	2.1 g
1,4-dithiothreitol	0.1050 mg	210.0 mg
Mannitol	21.0000 mg	42.0 g
0.01N NaOH or 0.01N HCl q.s. to	pH = 6	pH = 6
Water for Injections** q.s. to	1.05 ml	2.1 l

* including 15% overage to compensate for losses during manufacture

** during freeze-drying water for injections is removed

*** a 5% overfill of the bFGF sodium carboxymethyl-cellulose/DTT/mannitol solution is included

- 20 -

b) Formulation of bFGF composition stabilized with Polysorbated 80 and cysteine

	<u>Per vial***</u>	<u>per 2,000 vials ***</u>
FCE 26184*	0.0604 mg*	120.8 mg*
Cysteine	0.0105 mg	21.0 mg
1,4-dithiothreitol	0.1050 mg	210.0 mg
Mannitol	21.0000 mg	42.0 g
Polysorbate 80	0.0525 mg	105.0 mg
0.01N NaOH or 0.01N HCl q.s. to	pH = 6	pH = 6
Water for Injections** q.s. to	1.05 ml	2.1 l

* including 15% overage to compensate for losses during manufacture

** during freeze-drying water for injections is removed

*** a 5% overfill of the bFGF sodium carboxymethyl-cellulose/DTT/mannitol solution is included

Both formulations were freeze dried and individual vials are sealed under nitrogen.

- 21 -

c) Formulation of CM-FGF composition stabilised with sodium carboxymethylcellulose.

	<u>Per vial***</u>	<u>per 2,000 vials ***</u>
CM-FGF *	0.05 mg*	100 mg
Sodium carboxymethyl-cellulose	1.00 mg	2.0 g
1,4-dithiothreitol	0.10 mg	200.0 mg
Mannitol	20.00 mg	40.0 g
0.01N NaOH or 0.01N HCl q.s. to	pH = 6	pH = 6
Water for Injections** q.s. to	1.05 ml	2.1 l

* including 15% overage to compensate for losses during manufacture

** during freeze-drying water for injections is removed

*** a 5% overfill of the bFGF sodium carboxymethyl-cellulose/DTT/mannitol solution is included

- 22 -

d) Formulation of CM-FGF composition stabilized with Polysorbated 80 and cysteine

	<u>Per vial***</u>	<u>per 2,000 vials ***</u>
CM-FGF *	0.05 mg*	100.0 mg*
Cysteine	0.01 mg	20 mg
Mannitol	20 mg	40.0 g
Polysorbate 80	0.05 mg	100.0 mg
0.01N NaOH or 0.01N HCl q.s. to	pH = 6	pH = 6
Water for Injections** q.s. to	1.05 ml	2.1 l

* including 15% overage to compensate for losses during manufacture

** during freeze-drying water for injections is removed

*** a 5% overfill of the bFGF sodium carboxymethyl-cellulose/DTT/mannitol solution is included

Both formulations were freeze-dried and individual vials are sealed under nitrogen.

- 23 -

e) Formulation of CM-FGF composition stabilized with Polysorbated 80 and cysteine

	<u>Per vial***</u>	<u>per 2,000 vials***</u>
CM-FGF	0.05 mg*	100 mg*
Cysteine	0.01 mg	20 mg
1,4-Dithiothreitol	0.10 mg	200 mg
Mannitol	20 mg	40.0 g
Polysorbate 80	0.05 mg	100.0 mg
0.01N NaOH or 0.01 N HCl q.s. to	pH = 6	pH = 6
Water for Injections** q.s. to	1.05 ml	2.1 l

* including 15% overage to compensate for losses during manufacture

** during freeze-drying water for injections is removed

*** a 5% overfill of the bFGF sodium carboxymethyl-cellulose/DTT/mannitol solution is included

Both formulations were freeze dried and individual vials are sealed under nitrogen.

- 24 -

EXAMPLE 3Stability of Compositions of the Invention

Freeze dried vials containing compositions according to the present invention comprising about 50 µg of bFGF were examined for long term stability over various periods of time at different temperatures. The results are shown in Tables 3 to 22. The following parameters were examined and the acceptable standards are also given.

- Appearance : colourless glass vials
containing a compact, white
freeze-dried cake or mass,
determined by visual
inspection.
- Identification : * same molecular weight band as a
working standard of FCE 26184
or CM-FGF, under both reducing
and denaturing conditions, by
electrophoresis (SDS PAGE)
using the Phast System
(Registered Trade Mark),
available from Pharmacia LKB
Biotechnology, Uppsala, Sweden.

- 25 -

RP-HPLC assay	: 90-110% of the labelled amount
Bioassay (stimulation of DNA synthesis in 3T3 cells)	: $R = 1.0 \pm 0.35$, when the values expressed as titre of the formulation, calculated by a parallel line assay measured on ^3H -TdR incorporation in BALB/3T3 cells, using a FICE internal standard of FCE 26184.
Sterility	: sterile
Water	: not more than 3%
Appearance after reconstitution *	: clear and clean colourless solution, free from visible particles of foreign matter
pH after reconstitution *	: 5.0 - 7.0

* The vials are dissolved in 5 ml of the required solvent

Table 3- Accelerated stability data of FCE 26184 freeze-dried vials - Batch P8199/10/C
Active drug substance Batch No OP49

Composition of Example 2(a)

		25°C		
Tests	Initial			
	control	1 week	2 weeks	4 weeks
Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
. mcg/vial	49.88	50.93	49.63	52.07
. % initial	100.0	102.1	99.5	104.4
-Bioassay	n.d.	n.d.	n.d.	n.d.
-Water %	0.9	1.2	1.0	1.0
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	6.0	6.0	6.1	6.0

A= intense band at the correct MW

n.d. = not determined

Table 4 - Accelerated stability data of FCE 26184 freeze-dried vials -Batch P8199/10/C
Active drug substance Batch No OP49

Composition of Example 2(a)

Tests	Initial control	35°C		
		1 week	2 weeks	4 weeks
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
.mcg/vial	49.88	50.83	46.84	48.73
.% initial	100.0	101.9	93.9	97.7
-Bioassay	n.d.	n.d.	n.d.	n.d.
-Water %	0.9	0.8	0.9	0.9
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	6.0	5.9	6.0	6.0

A = intense band at the correct MW

n.d = not determined

TABLE 5 - Long term stability data of FCE 26184 freeze-dried
vials - Batch TF/23600 Active drug substance
Batch No. OP51/A

Composition of Example 2 (a)

Tests	Initial Control	2°C				
		2 mos	3 mos	6 mos	9 mos	12 mos
-Appearance	Complies	Unchanged				
-SDS PAGE	A	n.d.	A	n.d.	A	A
-RP-HPIC assay						
. mcg/vial	49.69	49.94	52.17	50.02	47.30	48.58
. % initial	100.00	100.5	105.0	100.7	95.1	97.8
-Bioassay	Within the limits	n.d.	n.d.	n.d.	Within the limits	Within the limits
-Water %	1.5	1.8	1.5	1.9	1.7	n.d.
-Appearance (reconstituted solution)	Complies	Unchanged				
-pH (reconstituted solution)	6.0	6.0	6.0	6.0	6.0	5.6

A = intense band at the correct MW

n.d. = not determined

TABLE 6 - Long term stability data of FCE 26184 freeze-dried
vials - Batch TF/23600 Active drug substance Batch
No. OP51/A

Composition of Example 2 (a)

Tests	Initial Control	8°C					
		2 mos.	3 mos.	4 mos.	6 mos.	9 mos.	12 mos.
-Appearance	Complies	unchanged					
-SDS PAGE	A	n.d.	A	n.d.	n.d.	A	A
-RP-HPLC assay							
. mcg/vial	49.69	49.02	52.97	49.09	50.49	50.50	49.46
. % initial	100.0	98.6	106.6	98.8	101.6	101.6	99.5
-Bioassay	Within the limits	Within the limits	n.d.	n.d.	n.d.	n.d.	n.d.
-Water%	1.5	1.0	1.2	1.4	1.6	1.6	n.d.
-Appearance (reconstituted solution)	Complies	unchanged					
-pH (reconstituted solution)	6.0	6.0	5.9	n.d.	6.0	5.9	5.7
-Sterility	sterile	n.d.	n.d.	n.d.	n.d.	n.d.	sterile

A = intense band at the correct MW

n.d. = not determined

TABLE 7 - Long term stability data of FCE 26184 freeze-dried
vials - Batch TF/23600 Active drug substance Batch
No. OP51/A

Composition of Example 2 (a)

Tests	Initial Control	15°C					
		2 mos.	3 mos.	4 mos.	6 mos.	9 mos.	12 mos.
-Appearance	Complies	Unchanged					
-SDS PAGE	A	n.d.	A	n.d.	n.d.	A	A
-RP-HPLC assay							
. mcg/vial	49.69	46.32	52.12	49.94	49.00	51.10	48.22
. % initial	100.0	93.2	104.9	100.5	98.6	103.0	97.0
-Bioassay	Within the limits	n.d.	n.d.	n.d.	n.d.	Within the limits	n.d.
-Water %	1.5	2.0	1.5	1.4	1.7	1.8	n.d.
-Appearance (reconstituted solution)	Complies	Unchanged					
-pH (reconstituted solution)	6.0	5.9	5.9	n.d.	6.0	5.9	5.7

A = intense band at the correct MW

n.d. = not determined

TABLE 8 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23600 Active drug substance Batch No. OP51/A

Composition of Example 2 (a)

Initial		25°C				
Tests	Control	1 mo.	2 mos.	3 mos.	4 mos.	6 mos. 9 mos. 12 mos.
-Appearance	Complies	-----Unchanged-----				
-SDS PAGE	A	A	n.d.	B	n.d.	B
-RP-HPLC assay						
. mcg/vial	49.69	49.35	48.33	46.21	45.22	43.70 n.d. 46.42
. % initial	100.0	99.3	97.3	93.0	91.0	87.9 n.d. 93.4
-Bioassay	Within the limits	n.d.	Within the limits	n.d.	n.d.	n.d. Within the limits
-Water %	1.5	1.5	1.8	1.7	1.8	1.7 1.8 1.7 n.d.
-Appearance (reconstituted solution)	Complies	-----Unchanged-----				
-pH	6.0	5.8	5.7	5.9	6.0	6.0 5.8 5.7
(reconstituted solution)						

A = intense band at the correct MW
 B = presence of secondary bands, both at higher MW
 n.d. = not determined.

TABLE 9 - Accelerated stability data of FCE 26184 freeze-dried vials - Batch TF/23600 Active drug substance Batch No. OP51/A

Composition of Example 2 (a)

		35°C			
Initial control		8 days	15 days	1 mo.	2 mos. 3 mos. 4 mos.
-Appearance	Complies	-----Unchanged-----			
-SDS PAGE	A	n.d.	n.d.	B	n.d. B n.d.
-RP-HPLC assay					
. mcg/vial	49.69	48.80	47.80	42.30	44.39 41.04 42.24
. % initial	100.00	98.2	96.2	85.1	89.3 82.6 85.0
-Bioassay	Within the limits	n.d.	n.d.	Within the limits	n.d. n.d.
-Water %	1.5	1.5	1.1	1.6	1.2 1.5 1.3
-Appearance (reconstituted solution)	Complies	-----Unchanged-----			
-pH	6.0	5.9	5.8	5.8	5.8 6.0 6.1
(reconstituted solution)					

A = intense band at the correct MW
 B = presence of secondary bands at higher MW
 n.d. = not determined

- 33 -

TABLE 10 - Accelerated stability data of FCE 26184
freeze-dried vials - Batch TF/23600 Active
drug substance Batch No. OP51/A
Composition of Example 2 (a)

Tests	Initial control	LCT + 100 F.C.		
		8 days	15 days	1 mo.
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	n.d.	n.d.	A
-RP-HPLC assay				
. mcg/vial	49.69	49.20	51.65	48.50
. % initial	100.0	99.0	103.9	97.6
-Bioassay	Within the limits	n.d.	n.d.	n.d.
-Water %	1.5	1.4	1.0	1.0
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	6.0	6.0	5.9	5.9

LCT = Light Cabinet Temperature ($28^{\circ} \pm 2^{\circ}\text{C}$)

F.C. = Foot Candles

A = intense band at the correct MW

n.d. = not determined

- 34 -

Table 11 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	2°C		
		2 mos.	6 mos.	9 mos.
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
. mcg/vial	49.43	49.38	50.18	47.18
. % initial	100.0	99.9	101.5	95.4
-Bioassay	Within the limits	n.d.	n.d.	Within the limits
-Water %	1.0	1.2	1.4	1.5
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	5.4	5.4	5.7	5.7

A = intense band at the correct MW

n.d. = not determined

- 35 -

Table 12 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	8°C			
		2 mos.	3 mos.	6 mos.	9 mos.
-Appearance	Complies	-----Unchanged-----			
-SDS PAGE	A	A	n.d.	n.d.	A
-RP-HPLC assay					
. mcg/vial	49.43	48.34	52.10	n.d.	45.46
. % initial	100.0	97.8	105.4	n.d.	92.0
-Bioassay	Within the limits	n.d.	n.d.	n.d.	n.d.
-Water %	1.0	1.2	1.1	1.3	1.1
-Appearance (reconstituted solution)	Complies	-----Unchanged-----			
-pH (reconstituted solution)	5.4	5.4	5.4	5.6	5.5
-Sterility	sterile	n.d.	n.d.	n.d.	n.d.

A = intense band at the correct MW

n.d. = not determined

- 36 -

Table 13 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	15°C			
		2 mos.	3 mos.	6 mos.	9 mos.
-Appearance	Complies	-----Unchanged-----			
-SDS PAGE	A	A	A	n.d.	A
-RP-HPLC assay					
. mcg/vial	49.43	49.03	49.8	52.25	46.32
. % initial	100.0	99.2	100.7	105.7	93.7
-Bioassay	Within the limits	n.d.	n.d.	n.d.	n.d.
-Water %	1.0	1.1	1.2	1.2	1.4
-Appearance (reconstituted solution)	Complies	-----Unchanged-----			
-pH (reconstituted solution)	5.4	5.4	5.4	5.6	5.4

A = intense band at the correct MW

n.d. = not determined

- 37 -

Table 14 - Long term stability data of FCE 26184 freeze-dried vials
 - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	25°C				
		1 mo.	2 mos.	3 mos.	6 mos.	9 mos.
-Appearance	Complies	-----Unchanged-----				
-SDS PAGE	A	A	A	A	n.d.	B
-RP-HPLC assay						
. mcg/vial	49.43	46.61	47.06	51.2	48.82	45.01
. % initial	100.0	94.3	95.2	103.6	98.8	91.1
-Bioassay	Within the limits	n.d.	n.d.	n.d.	n.d.	Within the limits
-Water %	1.0	1.2	1.1	1.1	1.2	1.2
-Appearance (reconstituted solution)	Complies	-----Unchanged-----				
-pH (reconstituted solution)	5.4	5.6	5.4	5.4	5.7	5.5

A = intense band at the correct MW

n.d. = not determined

- 38 -

Table 15 - Long term stability data of FCE 26184 freeze-dried vials
 - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	30°C				
		1 mo.	2 mos.	3 mos.	6 mos.	9 mos.
-Appearance	Complies	-----Unchanged-----				
-SDS PAGE	A	A	A	A	n.d.	n.d.
-RP-HPLC assay						
. mcg/vial	49.43	45.82	49.18	51.5	48.48	n.d.
. % initial	100.0	92.7	99.5	104.2	98.1	n.d.
-Bioassay	Within the limits	n.d.	n.d.	n.d.	n.d.	n.d.
-Water %	1.0	1.2	1.1	1.3	1.3	n.d.
-Appearance (reconstituted solution)	Complies	-----Unchanged-----				
-pH (reconstituted solution)	5.4	5.5	5.5	5.4	5.7	n.d.

A = intense band at the correct MW

n.d. = not determined

- 39 -

Table 16 - Accelerated stability data of FCE 26184 freeze-dried vials - Batch TF/23625 Active drug substance Batch No. OP48

Composition of Example 2(a)

Tests	Initial control	35°C		
		15 days	1 mo.	2 mos.
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
. mcg/vial	49.43	n.d.	45.18	48.14
. % initial	100.0		91.4	97.4
-Bioassay	Within the limits	n.d.	n.d.	n.d.
-Water %	1.0	1.5	1.4	1.2
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	5.4	5.5	5.5	5.5

A = intense band at the correct MW

n.d. = not determined

- 40 -

Table 17 - Long term stability data of FCE 26184 freeze-dried vials - batch P8199/10/I Active drug substance
Batch No. OP49

Composition of Example 2(b)

25°C

Tests	Initial control			
		1 week	2 weeks	4 weeks
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
. mcg/vial	51.08	53.58	n.d.	46.43
. % initial	100.0	104.9		90.9
-Bioassay	n.d.	n.d.	n.d.	n.d.
-Water %	0.8	0.9	0.9	1.0
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	6.0	6.2	6.1	6.2

A = intense band at the correct MW

n.d. = not determined

- 41 -

Table 18 - Accelerated stability data of FCE 26184 freeze-dried vials - Batch P8199/10/I Active drug substance
Batch No. OP49

Composition of Example 2(b)

Tests	Initial control	35°C		
		1 week	2 weeks	4 weeks
-Appearance	Complies	-----Unchanged-----		
-SDS PAGE	A	A	A	A
-RP-HPLC assay				
. mcg/vial	51.08	57.36	57.67	43.62
. % initial	100.0	112.3	112.9	85.4
-Bioassay	n.d.	n.d.	n.d.	n.d.
-Water %	0.8	0.8	0.8	0.9
-Appearance (reconstituted solution)	Complies	-----Unchanged-----		
-pH (reconstituted solution)	6.0	6.3	6.3	6.3

A = intense band at the correct MW

n.d. = not determined

- 42 -

Table 19 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23607 Active drug substance
Batch No. OP51/A

Composition of Example 2(b)

Tests	Initial control	2°C	
		2 mos.	3 mos.
-Appearance	Complies	----Unchanged----	
-SDS PAGE	A	A	A
-RP-HPLC assay			
. mcg/vial	52.13	50.93	51.56
. % initial	100.0	97.7	98.9
-Bioassay	Within the limits	n.d.	n.d.
-Water %	0.8	1.0	1.2
-Appearance (reconstituted solution)	Complies	----Unchanged----	
-pH (reconstituted solution)	6.1	6.4	6.3

A = intense band at the correct MW

n.d. = not determined

- 43 -

Table 20 - Long term stability data of FCE 26184 freeze-dried vials - Batch TF/23607 Active drug substance
Batch No. OP51/A

Composition of Example 2(b)

Tests	Initial control	25°C			
		1 mo.	2 mos.	3 mos.	4mos.
-Appearance	Complies	-----Unchanged-----			
-SDS PAGE	A	A	A	A	A
-RP-HPLC assay					
. mcg/vial	52.13	49.45	42.63	43.48	46.50
. % initial	100.0	94.9	81.8	83.4	89.1
-Bioassay	Within the limits	n.d.	Within the limits	n.d.	n.d.
-Water %	0.8	0.8	0.9	1.0	1.1
-Appearance (reconstituted solution)	Complies	-----Unchanged-----			
-pH (reconstituted solution)	6.1	6.3	6.2	6.1	6.3

A = intense band at the correct MW

n.d. = not determined

- 44 -

Table 21 - Accelerated stability data of FCE 26184 freeze-dried vials - Batch TF/23607 Active drug substance
Batch No. OP51/A

Composition of Example 2(b)

Tests	Initial control	35°C				
		8 days	15 days	1 mo.	2 mos.	3 mos.
-Appearance	Complies	-----Unchanged-----				
-SDS PAGE	A	A	A	A	A	A
-RP-HPLC assay						
. mcg/vial	52.13	52.15	47.85	41.95	36.90	34.87
. % initial	100.0	100.0	91.8	80.5	70.8	66.9
-Bioassay	Within the limits	n.d.	n.d.	Within the limits	n.d.	n.d.
-Water %	0.8	1.0	1.0	0.9	1.2	1.5
-Appearance (reconstituted solution)	Complies	-----Unchanged-----				
-pH (reconstituted solution)	6.1	6.3	6.3	6.3	6.3	6.1

A = intense band at the correct MW

n.d. = not determined

- 45 -

Table 22 - Accelerated stability data of freeze-dried vials -
Batch P4 Active drug substance Batch No. 910116-CM

Composition of Example 2(c)

Tests	Initial control	15 days		1 month		
		35°C	45°C	4°C	25°C	35°C
<hr/>						
-RP-HPLC assay						
. mcg/vial	53.54	n.d.	52.61	56.21	54.24	56.65
. % initial	100.0		98.2	105.0	101.3	105.8
<hr/>						

n.d. = not determined

Similar stability could be observed for the composition of
Examples 2(d) and 2(e).

- 46 -

SEQUENCE LISTING

(1) INFORMATION FOR SEQ ID NO:1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 155 amino acids
- (B) TYPE: amino acid
- (C) STRANDEDNESS: single
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO:1:

```

Met Ala Ala Gly Ser Ile Thr Thr Leu Pro Ala Leu Pro Glu Asp Gly
 1              5              10              15

Gly Ser Gly Ala Phe Pro Pro Gly His Phe Lys Asp Pro Lys Arg Leu
              20              25              30

Tyr Cys Lys Asn Gly Gly Phe Phe Leu Arg Ile His Pro Asp Gly Arg
          35              40              45

Val Asp Gly Val Arg Glu Lys Ser Asp Pro His Ile Lys Leu Gln Leu
 50              55              60

Gln Ala Glu Glu Arg Gly Val Val Ser Ile Lys Gly Val Cys Ala Asn
65              70              75              80

Arg Tyr Leu Ala Met Lys Glu Asp Gly Arg Leu Leu Ala Ser Lys Cys
          85              90              95

Val Thr Asp Glu Cys Phe Phe Phe Glu Arg Leu Glu Ser Asn Asn Tyr
          100              105              110

Asn Thr Tyr Arg Ser Arg Lys Tyr Thr Ser Trp Tyr Val Ala Leu Lys
          115              120              125

Arg Thr Gly Gln Tyr Lys Leu Gly Ser Lys Thr Gly Pro Gly Gln Lys
          130              135              140

Ala Ile Leu Phe Leu Pro Met Ser Ala Lys Ser
145              150              155

```

- 47 -

CLAIMS

1. A lyophilized composition which comprises a fibroblast growth factor (FGF), a pharmaceutically acceptable bulking agent and either

(a) an alkali metal salt of a carboxyalkyl
5 cellulose, or

(b) a polyoxyethylene sorbitan fatty acid ester and cysteine.

2. A composition according to claim 1 which additionally comprises an antioxidant.

10 3. A composition according to claim 2 in which the antioxidant is dithiothreitol.

4. A composition according to any one of the preceding claims in which the bulking agent is mannitol, lactose, polyvinylpyrrolidone, galactitol or trehalose.

15 5. A composition according to any one of the preceding claims in which the alkali metal salt of the carboxyalkyl cellulose is sodium carboxymethyl cellulose.

6. A composition according to any one of claims 1 to 4 which the polyoxyethylene fatty acid ester is
20 polysorbate 80.

7. A composition according to any one of the preceding claims in a sealed sterile glass vial.

8. A composition according to any one of the preceding claims wherein the fibroblast growth factor is
25 basic FGF.

9. A composition according to any one of claims 1 to 7 wherein the fibroblast growth factor is a basic FGF having the amino acid sequence from position 10 to position 155 shown in SEQ ID NO:1 in which the Cys residues at
30 positions 78 and 96 in SEQ ID NO:1 are carboxymethylated.

10. A kit comprising

(a) a composition according to any one of the preceding claims, and

(b) a sterile solution for reconstituting the

- 48 -

said composition.

11. A method of preparing a lyophilized composition containing a fibroblast growth factor (FGF) which comprises mixing, in aqueous solution, FGF, a
5 pharmaceutically acceptable bulking agent and either

(a) an alkali metal salt of a carboxyalkyl cellulose, or


(b) a polyoxyethylene sorbitan fatty acid ester and cysteine, and lyophilizing the aqueous solution.

10 12. A method for preparing an aqueous FGF solution which comprises reconstituting a composition according to any one of claims 1 to 9 with a sterile aqueous diluent.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 91/01330

I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
Int.Cl.5	A 61 K 9/14	A 61 K 47/20
A 61 K 47/32	A 61 K 47/38	A 61 K 47/14
II. FIELDS SEARCHED		
Minimum Documentation Searched?		
Classification System	Classification Symbols	
Int.Cl.5	A 61 K	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹		
Category ^o	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
A	EP,A,0345660 (TAKEDA) 13 December 1989, see the claims 1,4-5,12-13,15,18-19,24-25,27,29-30; page 2, lines 36-46; page 7, lines 4-7 ---	1,4,8-9,11-12
A	EP,A,0312208 (ETHICON) 19 April 1989, see the claims 1,3-4,10,16,18,22; page 3, lines 37,41-42; page 5, lines 42-52 ---	1,8-9,11-12
A	EP,A,0308238 (ETHICON) 22 March 1989, see the claims 1-2,4,6-9,15-19,21; page 3, lines 40-44; page 4, lines 7-9,19-27 (cited in the application) ---	1,4,8-12
A	EP,A,0267015 (ETHICON) 11 May 1988, see the claims 1-2,5,7; page 3, lines 29,33,41,57; page 4, lines 9,13; page 5, lines 11-12 --- -/-	1,2,4,8-9,11
<div style="display: flex; justify-content: space-between;"> <div style="width: 45%;"> <p>^o Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </div> <div style="width: 45%;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"A" document member of the same patent family</p> </div> </div>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
12-09-1991	21.10.91	
International Searching Authority	Signature of Authorized Officer	
EUROPEAN PATENT OFFICE	 M. van der Brink	

III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET)		
Category *	Citation of Document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
P, A	EP, A, 0406856 (TAKEDA) 9 January 1991, see the claims 1, 4-5, 7, 9; page 5, lines 20-24, 38-39 -----	11-12

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

EP 9101330

SA 49153

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on 26/09/91
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A- 0345660	13-12-89	AU-A- 3496989	07-12-89
		JP-A- 2138223	28-05-90
EP-A- 0312208	19-04-89	AU-A- 2223588	23-03-89
		JP-A- 2000112	05-01-90
EP-A- 0308238	22-03-89	AU-A- 2223688	23-03-89
		JP-A- 1121223	12-05-89
EP-A- 0267015	11-05-88	US-A- 4717717	05-01-88
		AU-A- 8064187	12-05-88
		JP-A- 63152324	24-06-88
EP-A- 0406856	09-01-91	CN-A- 1049106	13-02-91
		AU-A- 5879990	10-01-91